8-K/A
filed September 21, 2023, 7:59 PM ET
ticker DNTH
CIK 0001690585
M&A
confidence high
sentiment neutral
materiality 0.65
Dianthus files OpCo historical financials; pro forma cash runway into Q2 2026
Dianthus Therapeutics, Inc. /DE/
- OpCo net losses: $18.2M (H1 2023), $28.5M (FY2022), $13.1M (FY2021).
- Pro forma combined cash sufficient to fund operations into Q2 2026 per risk factors.
- Board classified: Class I (2025 AGM), Class II (2026 AGM), Class III (2024 AGM).
- Shares outstanding as of 9/21/2023: 14,813,295.
- Material weakness identified in internal control over financial reporting.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tomas Kiselak was appointed as Class II Director at Dianthus Therapeutics, Inc. /DE/.
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paula Soteropoulos was appointed as Class I Director at Dianthus Therapeutics, Inc. /DE/.
- Action
- appointed
- Role
- Class I Director
Exact text from the filing
As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jonathan Violin, Ph.D. was appointed as Class II Director at Dianthus Therapeutics, Inc. /DE/.
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Lei Meng was appointed as Class III Director at Dianthus Therapeutics, Inc. /DE/.
- Action
- appointed
- Role
- Class III Director
Exact text from the filing
As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Marino Garcia was appointed as Class I Director at Dianthus Therapeutics, Inc. /DE/.
- Action
- appointed
- Role
- Class I Director
Exact text from the filing
As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Leon O. Moulder, Jr. was appointed as Class III Director at Dianthus Therapeutics, Inc. /DE/.
- Action
- appointed
- Role
- Class III Director
Exact text from the filing
As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.